

Pan-Canadian Competitive Value Price Initiative for Generic Drugs

Alberta prices effective April 1, 2016

In 2013, the Council of the Federation, comprised of Canada's 13 provincial and territorial premiers, announced a price reduction to 18 per cent of the lowest brand price in participating provinces and territories for six drugs for the Pan-Canadian Competitive Value Price Initiative for Generic Drugs. In 2014 and 2015, a total of eight additional drugs were added.

This year, a further four drugs have been added to the Pan-Canadian Competitive Value Price Initiative for Generic Drugs: Donepezil Hydrochloride, Ezetimibe, Quetiapine Fumarate and Zopiclone. The Government of Alberta is taking steps to implement pricing for these drugs effective April 1, 2016.

Manufacturers have confirmed through a Pan-Canadian Price Confirmation process their ability to supply pharmacies in participating provinces and territories, including Alberta, the drugs included in this Initiative at the 18 per cent price reduction.

New pricing for drugs affected by this Initiative will become effective immediately on April 1, 2016. The *Alberta Drug Benefit List (ADBL)* will be updated at that time to reflect the change to the price of each of the drugs and the Least Cost Alternative (LCA) in the interchangeable grouping for these drugs.

A transition or washout period will not apply to drug products in this Initiative. Notification of prices is being provided at this time to allow pharmacies, manufacturers and wholesalers adequate time to adjust inventories and manage stocks.

Please see the below list of drug molecules included in the Pan-Canadian Competitive Value Price Initiative for Generic Drugs and the prices for the *ADBL* to be effective on April 1, 2016. Pharmacies must begin claiming the LCA amount for the drugs affected by this Initiative on April 1, 2016.

Please note that for currently listed drugs not affected by this Initiative, where there is a price reduction on April 1, 2016, a washout or transitional period of 30 days will continue to apply.

AMLODIPINE BESYLATE

2.5 MG (BASE) ORAL TABLET	\$ 0.1380
5 MG (BASE) ORAL TABLET	\$ 0.2417
10 MG (BASE) ORAL TABLET	\$ 0.3587

ATORVASTATIN CALCIUM

10 MG (BASE) ORAL TABLET	\$ 0.3138
20 MG (BASE) ORAL TABLET	\$ 0.3922
40 MG (BASE) ORAL TABLET	\$ 0.4216
80 MG (BASE) ORAL TABLET	\$ 0.4216

... continued from previous page

CITALOPRAM HYDROBROMIDE	
10 MG (BASE) ORAL TABLET	\$ 0.1432
20 MG (BASE) ORAL TABLET	\$ 0.2397
40 MG (BASE) ORAL TABLET	\$ 0.2397
CLOPIDOGREL BISULFATE	
75 MG (BASE) ORAL TABLET	\$ 0.4735
DONEPEZIL HYDROCHLORIDE	
5 MG ORAL TABLET	\$ 0.8255
10 MG ORAL TABLET	\$ 0.8255
EZETIMIBE	
10 MG ORAL TABLET	\$ 0.3260
GABAPENTIN	
100 MG ORAL CAPSULE	\$ 0.0749
300 MG ORAL CAPSULE	\$ 0.1821
400 MG ORAL CAPSULE	\$ 0.2171
METFORMIN HCL	
500 MG ORAL TABLET	\$ 0.0444
850 MG ORAL TABLET	\$ 0.0610
OLANZAPINE	
2.5 MG ORAL TABLET	\$ 0.3189
5 MG ORAL TABLET	\$ 0.6379
7.5 MG ORAL TABLET	\$ 0.9568
10 MG ORAL TABLET	\$ 1.2758
15 MG ORAL TABLET	\$ 1.9136
5 MG ORAL DISINTEGRATING TABLET	\$ 0.6434
10 MG ORAL DISINTEGRATING TABLET	\$ 1.2857
OMEPRAZOLE	
20 MG ORAL CAPSULE/SUSTAINED-RELEASE TABLET	\$ 0.4117
PANTOPRAZOLE	
40 MG ORAL ENTERIC-COATED TABLET	\$ 0.3628
QUETIAPINE FUMARATE	
25 MG (BASE) ORAL TABLET	\$ 0.0889
100 MG (BASE) ORAL TABLET	\$ 0.2372
200 MG (BASE) ORAL TABLET	\$ 0.4764
300 MG (BASE) ORAL TABLET	\$ 0.6953
RABEPRAZOLE SODIUM	
10 MG ORAL ENTERIC-COATED TABLET	\$ 0.1204
20 MG ORAL ENTERIC-COATED TABLET	\$ 0.2408

continued on next page ...

... continued from previous page

RAMIPRIL

1.25 MG ORAL CAPSULE/TABLET	\$ 0.1274
2.5 MG ORAL CAPSULE/TABLET	\$ 0.1470
5 MG ORAL CAPSULE/TABLET	\$ 0.1470
10 MG ORAL CAPSULE/TABLET	\$ 0.1862

ROSUVASTATIN CALCIUM

5 MG (BASE) ORAL TABLET	\$ 0.2311
10 MG (BASE) ORAL TABLET	\$ 0.2437
20 MG (BASE) ORAL TABLET	\$ 0.3046
40 MG (BASE) ORAL TABLET	\$ 0.3582

SIMVASTATIN

5 MG ORAL TABLET	\$ 0.1841
10 MG ORAL TABLET	\$ 0.3642
20 MG ORAL TABLET	\$ 0.4501
40 MG ORAL TABLET	\$ 0.4501
80 MG ORAL TABLET	\$ 0.4501

VENLAFAXINE HCL

37.5 MG (BASE) ORAL EXTENDED-RELEASE CAPSULE	\$ 0.1643
75 MG (BASE) ORAL EXTENDED-RELEASE CAPSULE	\$ 0.3285
150 MG (BASE) ORAL EXTENDED-RELEASE CAPSULE	\$ 0.3469

ZOPICLONE

5 MG ORAL TABLET	\$ 0.1782
7.5 MG ORAL TABLET	\$ 0.2250

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.587 2016/02